PSB202 (Qilu Pharmaceutical)

**PSB202** is an investigational, fixed-combination B-cell–depleting biologic developed by Qilu Pharmaceutical and Qilu Puget Sound Biotherapeutics. It is manufactured as a single product containing a 1:1 molecular ratio of two engineered, afucosylated humanized IgG1 monoclonal antibodies: PSB102, an Fc-enhanced type II anti-CD20 antibody, and PSB107, an anti-CD37 antibody. By co-targeting CD20 and CD37 on malignant and normal B cells, PSB202 induces direct target-mediated B-cell killing and promotes Fcγ receptor-mediated antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. It is in Phase 1 clinical development for previously treated relapsed or refractory CD20-positive indolent B-cell malignancies, including follicular lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, marginal zone lymphoma, mucosa-associated lymphoid tissue lymphoma, mantle cell lymphoma, and Waldenström macroglobulinemia.

Other names

PSB 202PSB202PSB-202